Under the influence of declining birth rates, expanding longevity, and changing population structures around the world, the global prevalence of senile dementia is expected to increase more than four-fold within the next forty years. Within the United States alone, the number of affected individuals over the age of 65 is expected to rise exponentially from 8 million cases (2% of the entire population in the year 2000), to 18 million retirees (roughly 4.5% of the national census in the year 2040). Although they are striking, these statistics quite likely underestimate the scope of the coming epidemic, as they fail to consider the impact of under-diagnosis, early-onset disease, and the potential for a changing incidence of illness in the context of increasingly toxic environments. In the face of this imminent crisis, concerned observers have called for policies and practices which aim to prevent, limit, or reverse dementia. Drug-Induced Dementia: A Perfect Crime is a timely resource which reveals why and how medical treatments themselves - specifically, psychopharmaceuticals - are a substantial cause of brain degeneration and premature death. A first-of-its-kind resource for patients and clinicians, the book integrates research findings from epidemiology (observational studies of patients in the "real world"), basic biology (animal experiments), and clinical science (neuroimaging and autopsy studies) in order to demonstrate the dementing and deadly effects of psychiatric drugs. Highlighted by more than 100 neuroimages, slides of tissue specimens, and illustrations, the book uniquely describes: the societal roots of the problem (target organ toxicity, regulatory incompetence, and performativity) the subtypes and essential causes of dementia the patterns, prevalence, and causes of dementia associated with antidepressants, antipsychotics, anxiolytics, mood stabilizers, and stimulants and the actions and reforms which patients, providers, and policy makers might immediately pursue, in an effort to mitigate the causes and consequences of this iatrogenic tragedy.

Under the influence of declining birth rates, expanding longevity, and changing population structures around the world, the global prevalence of senile dementia is expected to increase more than four-fold within the next forty years. Within the United States alone, the number of affected individuals over the age of 65 is expected to rise exponentially from 8 million cases (2% of the entire population in the year 2000), to 18 million retirees (roughly 4.5% of the national census in the year 2040). Although they are striking, these statistics quite likely underestimate the scope of the coming epidemic, as they fail to consider the impact of under-diagnosis, early-onset disease, and the potential for a changing incidence of illness in the context of increasingly toxic environments. In the face of this imminent crisis, concerned observers have called for policies and practices which aim to prevent, limit, or reverse dementia. Drug-Induced Dementia: A Perfect Crime is a timely resource which reveals why and how medical treatments themselves – specifically, psychopharmaceuticals – are a substantial cause of brain degeneration and premature death. A first-of-its-kind resource for patients and clinicians, the book integrates research findings from epidemiology (observational studies of patients in the "real world"), basic biology (animal experiments), and clinical science (neuroimaging and autopsy studies) in order to demonstrate the dementing and deadly effects of psychiatric drugs. Highlighted by more than 100 neuroimages, slides of tissue specimens, and illustrations, the book uniquely describes: Ø the societal roots of the problem(target organ toxicity, regulatory incompetence, and performativity) Ø the subtypes and essential causes of dementia Ø the patterns, prevalence, and causes of dementia associated with antidepressants, antipsychotics, anxiolytics, mood stabilizers, and stimulants and Ø the actions and reforms which patients, providers, and policy makers might immediately pursue, in an effort to mitigate the causes and consequences of this iatrogenic tragedy.

Emphasizing the relevance of recent findings to the differential diagnoses of a wide range of neurological conditions, this book offers an account of drug- induced neurological disorders. Specific chapters discuss epidemiology and clinical significance, pathomechanisms, encephalopathies, disorders of consciousness, neuropsychiatric disorders, headaches, seizures, movement disorders, cerebrovascular disorders, myopathies, diseases of the spine and spinal cord, cerebellar disorders, aseptic meningitis, benign intracranial hypertension, disorders of the automatic nervous system, sleep disorders, Eosinophilia Myalgia Syndrome, serotonin syndrome, Gillian-Barre syndrome, subacute myelo-optico-neuropathy, and pituitary disorders. Jain is a consultant in pharmaceutical medicine. Annotation copyrighted by Book News Inc., Portland, OR.

Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.

The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.

A veteran board-certified pharmacist cites the high number of annual deaths associated with prescription drug side effects, calling for changes in prescription practices that account for the needs of aging bodies.

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.

The second revised edition of this text will update and present current state of the art clinical approaches to this subject. This book will continue to be the source text of information on drug-induced movement disorders authored and edited by the pioneers in the field. It will be an invaluable addition to the library of any neurologist.